BioNano Genomics (BNGO) AI Stock Analysis

• Market Cap: $18.83M
• Dividend Yield: N/A
• Average Volume (3M): 303.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: -13.84%
• EPS Growth: 88.80%
• Country: US
• Employees: 98
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -2.04
• Shares Outstanding: 10,176,000
• 10 Day Avg. Volume: 232,330
• 30 Day Avg. Volume: 303,108
• PEG Ratio: <0.01
• Price to Book (P/B): 0.93
• Price to Sales (P/S): 1.07
• P/FCF Ratio: -0.48
• Enterprise Value/Market Cap: -0.29
• Enterprise Value/Revenue: -0.19
• Enterprise Value/Gross Profit: -0.41
• Enterprise Value/Ebitda: 0.19
• 1Y Price Target: $7.50
• Price Target Upside: 362.96% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $1.50 ▼(-7.41% Downside)

BioNano Genomics' overall stock score is primarily impacted by its financial performance, which is hindered by significant profitability and cash flow issues. Technical analysis indicates a bearish trend, and valuation metrics are weak due to the lack of profitability. Despite positive earnings call highlights, the financial and technical challenges weigh heavily on the overall score.

Positive Factors

Revenue Growth

The 21% revenue growth in Q3 2025 indicates strong market demand and effective sales strategies, supporting long-term business expansion.

Gross Margin Improvement

Improved gross margins suggest better cost management and operational efficiency, enhancing profitability potential over time.

Expansion of Optical Genome Mapping (OGM)

The growth in OGM publications indicates increasing adoption and validation of the technology, strengthening the company's market position.

Negative Factors

Declining Revenue Growth

The declining revenue growth trend poses a risk to long-term financial stability, potentially limiting future investment and expansion.

Negative Profitability

Persistent negative profitability challenges the company's ability to sustain operations and invest in growth without external funding.

Cash Flow Challenges

Negative cash flow growth indicates inefficiencies in cash generation, potentially impacting the company's ability to fund operations and growth initiatives.

BioNano Genomics Business Overview & Revenue Model

Company Description

BioNano Genomics (BNGO) is a biotechnology company focused on advancing the field of genomics through its innovative solutions for genome mapping and analysis. Operating in the life sciences sector, BNGO specializes in providing tools and technologies that enable researchers and clinicians to better understand genetic variations and their implications in health and disease. The company's core products include the Saphyr system, a platform designed for high-throughput genome mapping, and related consumables and software that facilitate genomic analysis.

How the Company Makes Money

BioNano Genomics generates revenue primarily through the sale of its Saphyr systems, consumables, and software solutions. The company has established a revenue model that includes the direct sale of its hardware and ongoing sales of consumables that are required for the operation of the Saphyr system. Additionally, BNGO benefits from software licensing and support services associated with their genomic analysis products. Significant partnerships with academic and research institutions, as well as collaborations with biopharmaceutical companies, contribute to its revenue by expanding the adoption of its technology in various research applications and clinical settings. The company may also receive funding through grants and strategic collaborations that support its product development and market expansion efforts.

BioNano Genomics Financial Statement Overview

Summary

BioNano Genomics faces significant profitability and cash flow challenges despite some revenue growth. The company struggles with negative margins and cash flow ratios, indicating ongoing financial difficulties. Improvements in leverage management are noted, but overall financial stability remains a concern.

Income Statement

BioNano Genomics shows a modest revenue growth rate of 4.72% TTM, but profitability remains a significant concern with a net profit margin of -271.02% and negative EBIT and EBITDA margins. The gross profit margin is low at 5.05%, indicating challenges in cost management. Overall, the company struggles with profitability despite some revenue growth.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.43 TTM, reflecting better leverage management compared to previous years. However, the return on equity remains negative at -167.22%, indicating ongoing profitability issues. The equity ratio is not provided, but the balance sheet shows a need for improved financial stability.

Cash Flow

Free cash flow growth is negative at -28.35% TTM, and the operating cash flow to net income ratio is -1.08, highlighting cash flow challenges. The free cash flow to net income ratio is 1.0, indicating that free cash flow aligns with net income, but both are negative, reflecting cash flow difficulties.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.72M	30.78M	36.12M	27.80M	17.98M	8.50M
Gross Profit	13.36M	380.00K	9.57M	5.95M	3.87M	2.77M
EBITDA	-28.58M	-97.47M	-213.60M	-120.31M	-73.86M	-35.57M
Net Income	-38.59M	-112.02M	-232.49M	-132.60M	-72.44M	-41.11M
Balance Sheet
Total Assets	79.06M	76.67M	214.40M	307.50M	377.10M	60.45M
Cash, Cash Equivalents and Short-Term Investments	3.06M	9.47M	66.77M	113.19M	250.61M	38.45M
Total Debt	7.37M	27.30M	79.41M	11.67M	10.70M	16.32M
Total Liabilities	29.26M	41.30M	118.25M	58.10M	39.98M	25.37M
Stockholders Equity	49.80M	35.38M	96.16M	249.40M	337.12M	35.08M
Cash Flow
Free Cash Flow	-18.67M	-69.03M	-126.87M	-128.12M	-73.39M	-38.31M
Operating Cash Flow	-18.67M	-68.92M	-125.18M	-124.82M	-71.93M	-38.31M
Investing Cash Flow	-13.76M	73.84M	24.16M	82.77M	-278.06M	-2.45M
Financing Cash Flow	26.33M	-13.69M	113.81M	23.01M	336.11M	61.90M

BioNano Genomics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.62
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNGO, the sentiment is Negative. The current price of 1.62 is below the 20-day moving average (MA) of 1.63, below the 50-day MA of 1.78, and below the 200-day MA of 3.18, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 48.81 is Neutral, neither overbought nor oversold. The STOCH value of 83.52 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BNGO.

BioNano Genomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLGT	60 Neutral	$881.62M	―	-3.80%	―	13.60%	74.64%
PSNL	57 Neutral	$952.87M	―	-43.69%	―	-21.02%	47.74%
BNR	54 Neutral	$121.79M	-6.04	-19.87%	―	5.44%	72.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYGN	49 Neutral	$658.09M	―	-72.52%	―	0.21%	-233.51%
BDSX	46 Neutral	$60.46M	-1.42	-302.55%	―	22.29%	31.93%
BNGO	40 Underperform	$18.83M	―	-78.22%	―	-13.84%	88.80%

BioNano Genomics Corporate Events

Bionano Genomics Reports Strong Q3 2025 Results

Bionano Genomics, Inc., a company specializing in genome analysis solutions, focuses on optical genome mapping (OGM) to assist researchers and clinicians in addressing complex genetic questions. In its latest earnings report, Bionano Genomics highlighted a strategic shift towards enhancing consumables and software utilization, which has contributed to a 21% increase in total revenue for the third quarter of 2025 compared to the same period in 2024. The company also reported a significant improvement in gross margins and a reduction in operating expenses.

BioNano Genomics Completes $9 Million Public Offering

On September 16, 2025, Bionano Genomics, Inc. announced a public offering of 5,000,000 shares of common stock and warrants, raising approximately $9 million in net proceeds, which will be used for working capital and general corporate purposes. The offering closed on September 17, 2025, with H.C. Wainwright & Co. acting as the exclusive placement agent, and the company agreed to certain restrictions on issuing additional shares for a specified period, impacting its financial strategy and market operations.

The most recent analyst rating on (BNGO) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioNano Genomics stock, see the BNGO Stock Forecast page.

Bionano Genomics’ Earnings Call: Cautious Optimism Amid Challenges

The recent earnings call for Bionano Genomics painted a picture of cautious optimism. While the company celebrated strong growth in flowcell sales and improved gross margins, it also faced challenges such as a decline in total revenue and a net decrease in the installed base of systems. Despite these hurdles, strategic advancements in software and consumables growth, along with new CPT codes, provide a hopeful outlook for future reimbursement opportunities.

Bionano Genomics Reports Q2 2025 Financial Results

Bionano Genomics is a company specializing in genome analysis solutions, offering optical genome mapping (OGM) systems, diagnostic services, and software for research and clinical applications. The company is recognized for its innovative approach to genome analysis and its platform-agnostic software solutions.